Please login to the form below

Not currently logged in
Email:
Password:

Sanofi wins Eloxatin patent case

A US district court has ruled in favour of Sanofi retaining marketing exclusivity for colorectal cancer treatment Eloxatin until August 2012 following a patent challenge from Sun Pharmaceuticals

A US district court has ruled in favour of Sanofi retaining marketing exclusivity for colorectal cancer treatment Eloxatin (oxaliplatin) until August 2012 following a patent challenge from Sun Pharmaceuticals.

Sun Pharma was appealing a district court ruling from April 2010 requiring Sun to cease selling its generic oxaliplatin products as of June 30, 2010.

Sanofi had previously reached settlement agreements with several other pharmaceutical companies, including Teva Pharmaceutical and Sandoz, prohibiting the sale of generic Eloxatin products in the US until August, 2012.

In recently released financial results, Sanofi reported the drug had sales €436m for Sanofi during the first half of 2011.

The company said it still sees Eloxatin as an important therapeutic option for healthcare professionals treating patients with colorectal cancer.

19th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics